Inovio Pharmaceuticals, Inc. insider trading

Every open-market purchase and sale by Inovio Pharmaceuticals, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Inovio Pharmaceuticals, Inc.’s insiders pay?

From February 4, 2011 to May 20, 2020, 11 insiders reported 39 open-market purchases and 44 sales not made under a pre-set plan in Inovio Pharmaceuticals, Inc. Twelve months after each purchase was reported, the shares were −24.1% against the S&P 500 on average (median −32.8%), over 11 purchases with a full year of prices; 18% beat the index. After sales, the shares moved −58.7% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 13, 2014 into $6,248 by November 2, 2026, −3.8% a year. It held shares 30% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $18,502 (+5.2% a year), and held throughout $47,602 (+13.7%).

Copying Inovio Pharmaceuticals, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Inovio Pharmaceuticals, Inc.'s insiders from August 13, 2014, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 30% of the time.

Inovio Pharmaceuticals, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Marxe Austin W & Greenhouse David M	10% owner	0	—	—	31	—	December 4, 2012
Kim Jong Joseph	Chief Executive Officer	13	−32.6% (1)	0%	5	−38.2% (1)	January 13, 2020
Collins Morton	Director	11	−39.3% (5)	0%	0	—	March 28, 2017
Kies Peter	CFO	4	−49.0% (1)	0%	2	−68.1% (1)	November 30, 2018
Benito Simon X	Director	2	+9.1% (1)	100%	3	−70.8% (2)	May 20, 2020
Sardesai Niranjan	Chief Operating Officer	3	+8.3% (2)	50%	1	−51.4% (1)	August 30, 2016
Cabrera Angel	Director	3	−12.9% (1)	0%	0	—	April 13, 2015
Weiner David B.	Director	0	—	—	2	−53.2% (1)	April 19, 2018
Bagarazzi Mark	Chief Medical Officer	1	—	—	0	—	April 16, 2013
Dhillon Avtar S	Executive Chairman	1	—	—	0	—	July 6, 2011
Humeau Laurent	Chief Scientific Officer	1	—	—	0	—	June 5, 2019

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Inovio Pharmaceuticals, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Inovio Pharmaceuticals, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged +11.8% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
October 30, 2015	2 buying	+10.7%	+63.4%	−2.2%
August 29, 2014	3 buying	−12.3%	−39.7%	−29.7%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Inovio Pharmaceuticals, Inc. · Funds · Politicians